Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45, 67.5, 90, and 112.5 mg Twice-Daily vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

NCT02006472 is registered in ClinicalTrials.gov with Prilenia as lead sponsor.

NCT NCT02006472
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02006472 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45, 67.5, 90, and 112.5 mg Twice-Daily vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Lead sponsor
Prilenia
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2014
Completion date
July 7, 2016
Enrollment
408 (actual)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

huntington's disease